Navigation Links
Nuvilex Launches Last Shot Hangover Remedy(TM) Web Site
Date:8/26/2009

CHERRY HILL, N.J., Aug. 26 /PRNewswire-FirstCall/ -- Nuvilex, Inc. (OTC Bulletin Board: NVLX), announces today the launch of its Last Shot Hangover Remedy(TM) ("Last Shot") web site at www.mylastshot.com. The newly released web site offers Nuvilex' customers product and use information, user testimonials, lists upcoming events, and fan page links to Facebook, Twitter, and YouTube social networking sites. Most importantly, the web site allows for the direct purchase of Last Shot for home use. Last Shot is available in a twelve shot party pack for $45.50 and a thirty-six shot large party pack for $129.50. On-line sales are offered a discount to the suggested retail price and include free shipping and handling. Last Shot Hangover Remedy(TM) is a groundbreaking nutritional supplement formulated to help ease the effects of alcohol consumption before they occur.

Nuvilex is initially concentrating its Last Shot brand awareness campaign to the Mid-Atlantic States region including New York City, Philadelphia and Baltimore and New York, New Jersey and Delaware beach resorts. The brand awareness campaign is targeted to facilitate organic growth through product trials, acceptance, and brand loyalty. The regional start is designed to perfect Last Shot's product advertising and promotion strategies, messaging, and sales techniques before a national launch.

Over 150 establishments are actively test marketing Last Shot as a product offering at distribution points including bars, hotels (mini-bar), and liquor and convenience stores. Skeptics and seasoned party people have put Last Shot to the test. A Philadelphia bar owner used one of his bartenders as a "guinea pig" before deciding to carry the product. Ryan, a South Street Philadelphia bartender shared, "I took one Last Shot before I started drinking and one when I was finished. . .and I really tied one on. I woke up the next morning with no headache, and I always get headaches when I drink. I felt as if I could go for a run!"

Bars that have picked up Last Shot are successfully generating sales through happy hour specials, featured mixed drinks, "shot girl" service, along with a station of Last Shot on ice by the exit for a final sale at closing. Last Shot venues are capitalizing on the opportunity to generate additional revenue.

Nuvilex has assembled an energetic team of recent college graduates for Last Shot product sales and promotional events. This team includes an event coordinator, product specialists, promotional models and an event photographer. Brand awareness has proven to be essential to closing Last Shot sales. A recent Friday night promotional event was held at Philadelphia's Buckhead Saloon (www.buckheadphilly.com) generating brand awareness among the over 500 attendees. Dan, a college graduate who tried Last Shot at the event shared, "If this product works, you have a customer for life!"

About Nuvilex, Inc.

Nuvilex, Inc. is an emerging healthcare consumer products company. The Company's lead products include: Last Shot Hangover Remedy, a unique sugar-free, calorie-free and caffeine-free liquid formula designed to ease the symptoms of a hangover; Cinnergen, which promotes a healthy glucose metabolism; Cinnechol, designed to help maintain normal cholesterol levels and support normal cardiovascular function; and Infinitink( (R)), a permanent yet more easily removable tattoo ink. The Company's complete portfolio spans aesthetics, skin care, environmental and nutraceutical products, all of which are designed to directly or indirectly improve human health. In March 2009, Nuvilex merged with Freedom2 Holdings, Inc., the developer of Infinitink( (R)). In conjunction with the merger, the Company changed its name to Nuvilex, Inc. from eFoodSafety.com. Please visit www.nuvilex.com for additional information on the Company.

Safe Harbor Statement

Statements contained in this presentation that are not strictly historical are "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities and Exchange Act of 1934. The forward-looking statements are made based on information available as of the date hereof, and the Company assumes no obligation to update such forward-looking statements. Forward-looking statements are sometimes identified by words such as "intends", "anticipates", "believes", "expects", and "hopes" and involve a number of risks and uncertainties that could cause the Company's actual results to differ materially from projected results. All parties are cautioned that such forward-looking statements involve risks and uncertainties that could cause the Company's actual results to differ materially from those in these forward-looking statements. Such risks and uncertainties include but are not limited to demand for the Company's products and services, the planned share exchange with Freedom2 Holdings, Inc., our ability to secure additional financing, and other factors that may be more fully described in reports to shareholders and periodic filings with the Securities and Exchange Commission.

    Company Contact:

    Blair Barnes
    Senior Vice President and Chief Financial Officer
    Nuvilex, Inc.
    Ph: 856-433-6088
    Email: bbarnes@nuvilex.com

    Press Contact:

    Pat Arcand
    Arcand & Madison
    Ph: 617-576-7777
    Email: pat@am-pr.com


'/>"/>
SOURCE Nuvilex, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Nuvilex to Issue Positive Shareholder Newsletter
2. Nuvilex Completes First Sale of Last Shot Hangover Remedy(TM)
3. Nuvilex, Inc. Announces Business Update Conference Call
4. Nuvilex Cites Study that Suggests Red Yeast Rice, an Active Ingredient in Cinnechol, Can Help to Improve Cardiovascular Health
5. Nuvilex Renews MedX Master Distribution Agreement and Implements New Pricing for Talsyn Scar Cream
6. Nuvilex Featured in Wall Street Reporter Interview
7. Nuvilex Offers Free Cinnergen Samples in Response to Spike in Consumer Interest
8. Nuvilex Launches Video Marketing Campaign
9. Nuvilex Gets Update from CK41 on purEffect(TM) Launch Plan
10. Nuvilex Signs Agreement with Jayhur Enterprises to Distribute Infinitink - the Worlds First Permanent, But Easier to Remove Tattoo Ink - in Australia and New Zealand
11. Time Magazine Reports on Infinitink Tattoo Ink From Nuvilex
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2017)... ... April 24, 2017 , ... ... prescription opioid overdose deaths now claim the lives of 62 Americans each day.(1) ... filings against drug manufacturers, distributors, pharmacies and prescribers by more than half.(2) ...
(Date:4/24/2017)... , ... April 24, 2017 , ... ... designed to recognize elevated anxiety levels in people with addiction who are served ... Smart Patch, a biosensing wearable device that monitors heart and breath rates to ...
(Date:4/24/2017)... (PRWEB) , ... April 24, 2017 , ... ... health of individuals with HIV because it is not known to have significant ... have favorable effects to both lower cholesterol levels and dampen inflammation in the ...
(Date:4/24/2017)... ... ... Come to PAINWeekEnd (PWE) Tampa on May 20 and 21, at the ... 2-day program. , An attendee at a recent PAINWeekEnd said, "Very helpful, wish ... course entitled Ain't Misbehavin': Decreasing and Managing Pain Patient Aberrant Behavior, presented by Dr. ...
(Date:4/24/2017)... FOREST KNOLLS, Calif. (PRWEB) , ... April 24, 2017 , ... ... and health topics, but she has not found any of them to be very ... weekly actions to slowly and easily make changes in their health. It prompted her ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... , April 20, 2017  Vivify Health, the pioneer ... has been awarded a very significant patent for the ... to continual care via digital health.  This landmark patent ... property and further secures Vivify,s position as the leader ... 2009, was the first company to apply consumer mobile ...
(Date:4/20/2017)... April 20, 2017 Research and Markets has ... Innovation Driven by Rapidly Expanding Injectables Market and Increasing Usage of ... ... delivery technologies will rise from USD 20 Billion in 2015 to ... Drug Delivery Technologies - Innovation Driven by Rapidly Expanding Injectables Market ...
(Date:4/20/2017)... Research and Markets has announced the ... Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies ... ... was valued at US$ 7,167.6 Mn in 2015, and is ... a CAGR of 5.6% from 2016 to 2024. ...
Breaking Medicine Technology: